This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Watanabe, H. et al. Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes. Sci. Transl Med. 15, 681 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tysoe, O. Sulfonylurea secondary failure mechanism identified. Nat Rev Endocrinol 19, 189 (2023). https://doi.org/10.1038/s41574-023-00815-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-023-00815-6
This article is cited by
-
Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far
Clinical Drug Investigation (2024)